Back to search results

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

Abroad (travel likely)Recruiting

Conditions

Schizophrenia Disorders

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • South London and Maudsley NHS Foundation Trust, London, Greater London, United Kingdom

    Contact: Study coordinator (Violeta Perez-Rodriguez, Clinical Research Associate) · violeta.perez_rodriguez@kcl.ac.uk · (+44)07871777185
    Contact: Study coordinator (Zeryab Meyer, Clinical Research Associate) · zeryab.meyer@kcl.ac.uk
    Contact: Principal Investigator (Katherine Beck, Clinical Lecturer)
    Violeta Perez-Rodriguez, Clinical Research Associate (Sub-investigator)
    Zeryab Meyer, Clinical Research Associate (Sub-investigator)
    Oliver Howes, Professor (Sub-investigator)
    Mitul Mehta, Professor (Sub-investigator)
    David Lythgoe, Senior Research Fellow (Sub-investigator)

  • Department of Computer Science, Faculty of Engineering Science, University College London, London, Greater London, United Kingdom

    Contact: Study coordinator (Rick Adams, Professor) · rick.adams@ucl.ac.uk
    Contact: Principal Investigator (Rick Adams, Professor)

  • School of Psychology, University of birmingham, Birmingham, United Kingdom

    Contact: Study coordinator (Rachel Upthegrove, Professor) · r.upthegrove@bham.ac.uk
    Contact: Principal Investigator (Rachel Upthegrove, Professor)
Study leads

  • Katherine Beck, Clinical Lecturer

    Principal Investigator

    Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience

View source on ClinicalTrials.gov(opens in a new tab)